Company Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases.
Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.
The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology.
Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Sumit Aggarwal M.B.A. |
Contact Details
Address: 480 Arsenal Way, Suite 130 Watertown, Massachusetts 02472 United States | |
| Phone | 781-577-5300 |
| Website | eloxxpharma.com |
Stock Details
| Ticker Symbol | ELOX |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001035354 |
| CUSIP Number | 29014R103 |
| ISIN Number | US29014R2022 |
| Employer ID | 84-1368850 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sumit Aggarwal M.B.A. | President, Chief Executive Officer and Director |
| Daniel E. Geffken M.B.A. | Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Barbara Ryan | Investor Relations Officer |
| Dr. Ali Hariri M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 25-NSE | Filing |
| Mar 14, 2024 | 8-K | Current Report |
| Jan 25, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 24, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 9, 2024 | 8-K | Current Report |
| Dec 28, 2023 | 8-K | Current Report |
| Dec 15, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 8-K | Current Report |